News
Media
Conferences
Partners
Publications
Events
CME/CE
Resources
PBM Directory
Subscribe

Spotlight -

Predictions for 2026: Our January 2026 issue|

MHE State of the Industry survey|

AMCP Nexus 2025|

2025 Fall Clinical Dermatology|

Opinion|Videos|August 21, 2024

PDTs as a Part of Integrative Care and Evaluating Patient Outcomes With PDTs

Author(s)Arwen Podesta, MD

Arwen Podesta, MD, examines the role of photodynamic therapies in integrative care and assess how they impact patient outcomes.

Episodes in this series

EP. 1 Understanding Prescription Digital Therapeutics: Definition, FDA Review and Clinical Impact

EP. 1 Understanding Prescription Digital Therapeutics: Definition, FDA Review and Clinical Impact

EP. 2 Promising Therapeutic Areas for PDTs and Addressing Unmet Needs in Mental Health

EP. 2 Promising Therapeutic Areas for PDTs and Addressing Unmet Needs in Mental Health

EP. 3 Benefits and Safety of PDTs

EP. 3 Benefits and Safety of PDTs

EP. 4 PDTs as a Part of Integrative Care and Evaluating Patient Outcomes With PDTs

EP. 4 PDTs as a Part of Integrative Care and Evaluating Patient Outcomes With PDTs

EP. 5 Communicating PDT Benefits to Patients and Clinician Training for Implementation

EP. 5 Communicating PDT Benefits to Patients and Clinician Training for Implementation

EP. 6 Successful PDT Implementation: Examples and Key Strategies

EP. 6 Successful PDT Implementation: Examples and Key Strategies

EP. 7 Managed Care Strategies for Ensuring Patient Access to PDTs

EP. 7 Managed Care Strategies for Ensuring Patient Access to PDTs

EP. 8 Managed Care Challenges and Solutions for PDT Coverage, and Evaluating Patient Outcomes and Satisfaction

EP. 8 Managed Care Challenges and Solutions for PDT Coverage, and Evaluating Patient Outcomes and Satisfaction

EP. 9 K-Cast Written Summary. Prescription Digital Therapeutics – Addressing Unmet Needs Among Patients With Mental Health Conditions

EP. 9 K-Cast Written Summary. Prescription Digital Therapeutics – Addressing Unmet Needs Among Patients With Mental Health Conditions

What are some of the benefits of prescription digital therapeutics (PDTs) for patients and providers?
How can PDTs help improve patient adherence to treatment?
How can PDTs help improve patient engagement and self-management of their health condition?

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Related Content

2 experts are featured in this series

Practical Takeaways for Patients, Providers, and Payers

ByJulia Rotow, MD ,Ibiayi Dagogo-Jack, MD

December 22nd 2025

man applying hand cream | Image credit: Africa Studio - stock.adobe.com

Top 5 most-read stories out of the 2025 AAD annual meeting

ByLaura Joszt, MA

December 17th 2025

2 experts are featured in this series

Limitations of Current Evidence for BRAF V600E-Mutant Metastatic NSCLC and Cross-Trial Comparisons

ByJulia Rotow, MD ,Ibiayi Dagogo-Jack, MD

December 15th 2025

2 experts are featured in this series

CNS Disease Considerations and Implications for Treatment Selection for BRAF V600E-Mutant Metastatic NSCLC

ByJulia Rotow, MD ,Ibiayi Dagogo-Jack, MD

December 15th 2025

2 experts are featured in this series

Practical Monitoring Strategies and Early Treatment Assessments in Patients with BRAF V600E-Mutant Metastatic NSCLC

ByJulia Rotow, MD ,Ibiayi Dagogo-Jack, MD

December 8th 2025

Latest CME

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Misty D. Shields, MD, PhD; Rujul Parikh, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Charu Aggarwal, MD, MPH, FASCO; Yifan Tu, MD, PhD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Charu Aggarwal, MD, MPH, FASCO; Mo Ziari, MD

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Zofia Piotrowska, MD, MHS; Shan Guo, MD

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Misty D. Shields, MD, PhD; Michelle Ojemuyiwa, MD

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Huntington Beach Symposia

In-Person + Virtual Event

Huntington Beach Symposia

February 19-21, 2026

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

3rd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

3rd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

David R. Gandara, MD; Roy S. Herbst, MD, PhD; Heather A. Wakelee, MD, FASCO

The 4th Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

The 4th Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

David R. Gandara, MD; Nicolas Villanueva, MD

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

Manmeet Ahluwalia, MD, MBA

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

Zofia Piotrowska, MD, MHS; Bruna Pellini, MD; Alice Shaw, MD, PhD

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Marina Chiara Garassino, MD; Sarah Goldberg, MD, MPH; Biagio Ricciuti, MD, PhD

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

Jacob Sands, MD; Anne Chiang, MD, PhD; Alissa J. Cooper, MD

22nd Annual Winter Lung Cancer Conference®

22nd Annual Winter Lung Cancer Conference®

Julie Brahmer, MD; Rogerio C. Lilenbaum, MD, FACP, FASCO; Mark A. Socinski, MD

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Fred Hirsch, MD, PhD, FASCO; Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Fred Hirsch, MD, PhD, FASCO; Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

Lauren Averett Byers, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Jacob Sands, MD; Jennifer Carlisle, MD; Hossein Borghaei, DO, MS

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Benjamin P. Levy, MD; Ticiana Leal, MD; Aaron Lisberg, MD; Christine M. Lovly, MD, PhD, FASCO

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Trending on Managed Healthcare Executive

7 things you need to know about the PBM reforms signed into law this week

PBM reform. It has finally happened

TrumpRx launches; some experts question its long-term value

FDA issues draft guidance on MRD and complete response as primary endpoints for accelerated multiple myeloma drug approvals

Cancer survival fell and deaths rose during first two years of COVID-19